Time

Topic

Speaker

Moderator: Bradley Sumrall, MD

8:00 – 8:10 AM

Welcome and Day Overview

• Sagar Lonial, MD, FACP, FASCO
• Suresh Ramalingam, MD, FACP, FASCO

Thoracic Cancer

8:10 – 8:30 AM

DEBATE: ADCs are Highly Promising for the Treatment of NSCLC

8:10 – 8:18 AM

Pro

• Conor E. Steuer, MD

8:18 – 8:26 AM

Con

• Ticiana Leal, MD

• Jennifer Carlisle, MD

8:26 – 8:30 AM

Rebuttals and Discussion

8:30 – 8:45 AM

New Developments in Treatment of SCLC

• Ticiana Leal, MD

8:45 – 9:00 AM

Targeting EGFR: What is New?

• Suresh Ramalingam, MD, FACP, FASCO

9:00 – 9:15 AM

Stage III Unresectable NSCLC

• Sibo Tian, MD

9:15 – 9:30 AM

Immunotherapy for Early-Stage NSCLC

• Jennifer Carlisle, MD

9:30 – 9:50 AM

Patient-Based Panel Discussion with ASCO Highlights and Q&A

All speakers

Pt case presented by Winship fellow

9:50 – 10:10 AM

BREAK

Head and Neck

10:10 – 10:25 AM

Promising Combinations with Immune Checkpoint Inhibitors 
in the Treatment of RMHNSCC

• Nabil Saba, MD, FACP

10:25 – 10:45 AM

DEBATE: ctDNA Needs to be Included in the Management of HPV-Related OPSCC

10:25 – 10:33 AM

Yes

• Conor E. Steuer, MD

10:33 – 10:41 AM

No

• William (Bill) Stokes, MD

10:41 – 10:45 AM

Rebuttals and Discussion

10:45 – 11:05 AM

Patient-Based Panel Discussion with ASCO Highlights and Q&A

All speakers

Pt case presented by Winship fellow

Lecture of the Day

11:05 – 11:25 AM

Should I Use AI to Improve Efficiency in the Clinic? 
Opportunities and Pitfalls

• Ravi B. Parikh, MD, MPP, FACP

11:25 AM – 12:10 PM

LUNCH

Moderator: Steven McCune, MD

Leukemia

12:10 – 12:30 PM

DEBATE: Early vs Delayed Transplantation in Myelofibrosis

12:10 – 12:18 PM

Early

• Amelia Langston, MD

12:18 – 12:26 PM

Delayed

• Michael Hochman, MD

12:26 – 12:30 PM

Rebuttals and Discussion

12:30 – 12:45 PM

Targeted Treatment with Menin Inhibitors

• Martha Arellano, MD

12:45 – 1:00 PM

Emerging Targets in MPNs

• Anthony Hunter, MD

1:00 – 1:15 PM

Contemporary Management of Low-Risk MDS

• Colin Vale, MD

1:15 – 1:30 PM

CD19 Targeting in B-ALL: When to Use CAR T-Cells vs T-Cell Engagers

• Martha Arellano, MD

1:30 – 1:45 PM

Contemporary Management of CML

• Hagop Kantarjian, MD

1:45 – 2:05 PM

Patient-Based Panel Discussion with EHA Highlights and Q&A

All speakers

Pt case presented by Winship fellow

2:05 PM

Closing Comments and Adjourn

• Sagar Lonial, MD, FACP, FASCO

6:00 – 8:00 PM

Welcome Dinner at Beach Club (Name badges required for entry)

Time

Topic

Speaker

Moderator: Eric Turner, MD

7:30 – 7:35 AM

Welcome and Day Overview

• Suresh Ramalingam, MD, FACP, FASCO

Lymphoma

7:35 – 7:50 AM

How I Manage Patients With DLBCL Who Don’t Achieve 
a Metabolic Complete Remission With Primary Therapy

• James O. Armitage, MD

7:50 – 8:05 AM

Optimal Frontline Therapy for MCL

• Jonathon B. Cohen, MD, MS

8:05 – 8:20 AM

How To Sequence Treatments for Relapsed FL

• Jean Koff, MD, MS

8:20 – 8:40 AM

DEBATE: MRD Is a Useful Tool in the Management of Patients with CLL

8:20 – 8:28 AM

Pro

• Susan M. O’Brien, MD

8:28 – 8:36 AM

Con

• Andres Chang, MD, PhD

8:36 – 8:40 AM

Rebuttals and Discussion

8:40 – 8:55 AM

Update in the Management of PTCL: Focus on Recent Data 
and Upcoming Studies

• Mary Jo Lechowicz, MD

8:55 – 9:15 AM

DEBATE: All Eligible Patients with Relapsed HL Should Receive an Autologous Transplant

8:55 – 9:03 AM

Pro

• Amelia Langston, MD

9:03 – 9:11 AM

Con

• Jonathan B. Cohen, MD, MS

9:11 – 9:15 AM

Rebuttals and Discussion

9:15 – 9:35 AM

Patient-Based Panel Discussion with EHA Highlights and Q&A

All speakers

Pt case presented by Winship fellow

9:35 – 9:55 AM

BREAK

Melanoma

9:55 – 10:10 AM

Current and Future Options for Anti-PD1 
Resistant Metastatic Melanoma

• Michael B. Atkins, MD

10:10 – 10:30 AM

DEBATE: Best Neoadjuvant Option For Resectable Melanoma

10:10 – 10:18 AM

Pembrolizumab

• Michael Lowe, MD, MA

10:18 – 10:26 AM

Nivolumab/Ipilimumab (Flip Dose)

• Melinda Yushak, MD, MPH

10:26 – 10:30 AM

Rebuttals and Discussion

Brain Cancers

10:30 – 10:45 AM

Methylation Profiling – The New Gold Standard 
for Brain Tumor Diagnoses

• Edjah K. Nduom, MD, FAANS

10:45– 11:00 AM

Biomarker-Driven, Targeted-Inhibitor Therapies in Neuro-Oncology: 
What are we Missing?

• Byram Ozer, MD, PhD

25th Anniversary Keynote Lecture

11:00 – 11:30 AM

25 Years of the Evolution of Cancer Care: What Have 
We Accomplished and Where are We Going?

• Fadlo Khuri, MD

11:30 AM – 12:25 PM

Lunch

Moderator: Frederick Flynt, MD

Genitourinary Cancers

12:25 – 12:45 PM

DEBATE: Optimal Approach to Muscle-Invasive Bladder Cancer

12:25 – 12:33 PM

Perioperative Immunotherapy

• Jacqueline Brown, MD

12:33 – 12:41 PM

Immunotherapy

• Vikram M. Narayan, MD

12:41 – 12:45 PM

Rebuttals and Discussion

12:45 – 1:00 PM

Advancing Care in Metastatic Hormone-Sensitive Prostate Cancer

• Jacob E. Berchuck, MD

1:00 – 1:15 PM

Management of mCRPC in 2025: New Data and Future Directions

• Bradley Carthon, MD, PhD

1:15 – 1:30 PM

Perioperative Treatment in RCC

• Mehmet Asim Bilen, MD

1:30 – 1:50 PM

DEBATE: Optimal Treatment of Oligometastatic Prostate Cancer

1:30 – 1:38 PM

Local Therapy

• Ashesh Jani, MD, MSEE, FASTRO

1:38 – 1:46 PM

Systemic Therapy

•  Jordan Ciuro, MD

1:46 – 1:50 PM

Rebuttals and Discussion

1:50 – 2:10 PM

Patient-Based Panel Discussion with ASCO Highlights and Q&A

All speakers

Pt case presented by Winship fellow

2:10 PM

Closing Comments and Adjourn

• Sagar Lonial, MD, FACP, FASCO

2:30 PM

Georgia Blood Cancer Trials Network Meeting
Open to all

• Jonathon B. Cohen, MD, MS

Time

Topic

Speaker

Moderator: Duane Moores, MD

8:00 – 8:05 AM

Welcome and Day Overview

• Suresh Ramalingam, MD, FACP, FASCO

Gastrointestinal Cancers

8:05 – 8:25 AM

DEBATE: Choice of Frontline Therapy for Advanced HCC

8:05 – 8:13 AM

VEGF + IO

• Lindsay Hannan, MD, MSc

8:13 – 8:21 AM

IO + IO

• Olumide Gbolahan, MBBS, MSc

8:21 – 8:25 AM

Rebuttals and Discussion

8:25 – 8:40 AM

Novel and Targeted Therapies in Cholangiocarcinoma

• Ruoyu Miao, MD

8:40 – 8:55 AM

Targeted Therapies in Advanced Colorectal Cancer: 
Beyond RAS and BRAF

• Olatunji Alese, MD

8:55 – 9:10 AM

It’s All Greek to Me: Alpha, Beta, and Gamma Emitters 
in Theranostics for Pancreatic NETs

• Daniel M. Halperin, MD

9:10 – 9:30 AM

DEBATE: The Role of Surgery in MSI-High Rectal Cancer

9:10 – 9:18 AM

Pro

• Patrick Sullivan, MD, FACS

9:18 – 9:26 AM

Con

• Oluwadunni E. Emiloju, MBBS, MS

9:26 – 9:30 AM

Rebuttals and Discussion

9:30 – 9:50 AM

Patient-based Panel Discussion with ASCO Highlights and Q&A

All speakers

Pt case presented by Winship fellow

9:50 – 10:10 AM

BREAK

10:10 – 10:25 AM

Updates in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

• Charles Staley, MD

Gynecologic Cancers

10:25 – 10:40 AM

Recurrent Ovarian Cancer: Incorporating New Agents 
and Sequencing Therapies

• Jennifer M. Scalici, MD

10:40 – 10:55 AM

Focusing on Newer Therapies Therapies in Advanced or 
Recurrent Endometrial Cancer: Where Are We Now?

• Susan Modesitt, MD, FACOG, FACS

10:55 – 11:10 AM

Managing Off-Target Toxicity in Gynecologic Cancers 
with New Therapies

• Beryl Manning-Geist, MD

11:10 – 11:30 AM

Patient-based Panel Discussion with ASCO Highlights and Q&A

All speakers

Pt case presented by Winship fellow

11:30 AM – 12:15 PM

LUNCH

Moderator: Sope Olugbile, MD

Myeloma

12:15 – 12:30 PM

Smoldering MM: What We Know and Where We Are Going

• Sagar Lonial, MD, FACP, FASCO

12:30 – 12:45 PM

Quadruplets vs Triplets for Elderly Patients with MM

• Nisha Joseph, MD

12:45 – 1:05 PM

DEBATE: Optimal Patient Phenotype in Relapsed MM

12:45 – 12:53 PM

CAR T-Cells

• Ajay K. Nooka, MD, MPH, FACP

12:53 – 1:01 PM

Bispecific Antibodies

• Nisha Joseph, MD

1:01 – 1:05 PM

Rebuttals and Discussion

1:05 – 1:20 PM

Leveraging MRD for Treatment Escalation vs De-Escalation

• Jonathan Kaufman, MD

1:20 – 1:35 PM

Novel Targets and Newer Drugs in MM

• Kenneth C. Anderson, MD

1:35 – 1:55 PM

Patient-based Panel Discussion with EHA Highlights and Q&A

All speakers

Pt case presented by Winship fellow

1:55 PM

Closing Comments and Adjourn

• Sagar Lonial, MD, FACP, FASCO

5:00 – 6:30 PM

Closing Reception at Beach Club (Name badges required for entry)

Time

Topic

Speaker

Moderator: Kristy McDonald, MD

8:00 – 8:05 AM

Welcome and Day Overview

• Suresh Ramalingam, MD, FACP, FASCO

Breast Cancer

8:05 – 8:20 AM

Updates in Metastatic HR+/HER2- Metastatic Breast Cancer

• Kevin Kalinsky, MD, MS, FASCO

8:20 – 8:40 AM

DEBATE: Omission of Sentinel Lymph Node Biopsy

8:20 – 8:28 AM

Pro

• Cletus Arciero, MD, FACS

8:28 – 8:36 AM

Con

• Mylin A. Torres, MD

8:36 – 8:40 AM

Rebuttals and Discussion

8:40 – 8:55 AM

Triple Negative Breast Cancer: Where Are We 
and Where Are We Going?

• Shipra Gandhi, MD, MS

8:55 – 9:10 AM

Optimizing Survivorship

• Neil M. Iyengar, MD

9:10 – 9:30 AM

DEBATE: Is There a Role for Checking ctDNA in Early-Stage Breast Cancer?

9:10 – 9:18 AM

Yes

• Manali Bhave, MD

9:18 – 9:26 AM

No

• Elizabeth Sakach, MD

9:26 – 9:30 AM

Rebuttals and Discussion

9:30 – 9:45 AM

Treatment Approaches in HER2 Positive Breast Cancer

• Jane Lowe Meisel, MD, FASCO

9:45 – 10:05 AM

Patient-based Panel Discussion with ASCO Highlights and Q&A

All speakers

Pt case presented by Winship fellow

10:05 – 10:10 AM

Closing Comments and Adjourn

• Sagar Lonial, MD, FACP, FASCO
• Suresh Ramalingam, MD, FACP, FASCO